Total Payments
$6,895
2024 Payments
$1,264
Companies
5
Transactions
28
Payment Breakdown by Category
Research$3,548 (51.5%)
Travel$2,584 (37.5%)
Food & Beverage$763.00 (11.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,548 | 11 | 51.5% |
| Travel and Lodging | $2,584 | 9 | 37.5% |
| Food and Beverage | $763.00 | 8 | 11.1% |
Payments by Type
Research
$3,548
11 transactions
General
$3,347
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $2,633 | 7 | $0 (2017) |
| ModernaTX, Inc. | $1,264 | 3 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,232 | 10 | $0 (2018) |
| Eli Lilly and Company | $914.50 | 4 | $0 (2022) |
| Novo Nordisk AS | $851.09 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,264 | 3 | ModernaTX, Inc. ($1,264) |
| 2022 | $291.00 | 1 | Eli Lilly and Company ($291.00) |
| 2021 | $194.00 | 1 | Eli Lilly and Company ($194.00) |
| 2020 | $429.50 | 2 | Eli Lilly and Company ($429.50) |
| 2018 | $1,232 | 10 | Merck Sharp & Dohme Corporation ($1,232) |
| 2017 | $3,484 | 11 | Allergan Inc. ($2,633) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $546.95 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $531.06 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $186.00 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $291.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 01/29/2021 | Eli Lilly and Company | — | — | In-kind items and services | $194.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 08/24/2020 | Eli Lilly and Company | — | — | In-kind items and services | $342.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $87.00 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 04/03/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Travel and Lodging | Cash or cash equivalent | $56.48 | General |
| Category: VACCINE | ||||||
| 03/23/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: VACCINE | ||||||
| 03/23/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: VACCINE | ||||||
| 03/23/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $42.00 | General |
| Category: VACCINE | ||||||
| 03/23/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Travel and Lodging | In-kind items and services | $25.12 | General |
| Category: VACCINE | ||||||
| 03/22/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Travel and Lodging | In-kind items and services | $607.52 | General |
| Category: VACCINE | ||||||
| 03/22/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Travel and Lodging | In-kind items and services | $240.88 | General |
| Category: VACCINE | ||||||
| 03/22/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $85.00 | General |
| Category: VACCINE | ||||||
| 03/22/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: VACCINE | ||||||
| 03/22/2018 | Merck Sharp & Dohme Corporation | V160 (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VACCINE | ||||||
| 03/16/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $252.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 02/28/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $546.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 02/14/2017 | Allergan Inc. | ESTRACE CREAM (Drug) | — | Cash or cash equivalent | $225.00 | Research |
| Study: A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF THREE DOSES OF ESTRADIOL VAGINAL CAPSULE IN POSTMENOPAUSAL WOMEN WITH VULVOVAGINAL ATROPHY • Category: WOMENS HEALTH | ||||||
| 02/07/2017 | Allergan Inc. | ESTRACE CREAM (Drug) | — | Cash or cash equivalent | $660.00 | Research |
| Study: A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF THREE DOSES OF ESTRADIOL VAGINAL CAPSULE IN POSTMENOPAUSAL WOMEN WITH VULVOVAGINAL ATROPHY • Category: WOMENS HEALTH | ||||||
| 02/03/2017 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $275.00 | General |
| 02/03/2017 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $272.50 | General |
| 02/03/2017 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $204.83 | General |
| 02/03/2017 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $98.76 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,403 | 4 |
| A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF THREE DOSES OF ESTRADIOL VAGINAL CAPSULE IN POSTMENOPAUSAL WOMEN WITH VULVOVAGINAL ATROPHY | Allergan Inc. | $885.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $827.50 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $345.00 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $87.00 | 1 |
About Dr. Michele Reynolds, M.D
Dr. Michele Reynolds, M.D is a Family Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174578413.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michele Reynolds, M.D has received a total of $6,895 in payments from pharmaceutical and medical device companies, with $1,264 received in 2024. These payments were reported across 28 transactions from 5 companies. The most common payment nature is "" ($3,548).
Ad
Practice Information
- Specialty Family Medicine
- Location Dallas, TX
- Active Since 05/24/2006
- Last Updated 08/13/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1174578413
Products in Payments
- V160 (Biological) $1,232
- ESTRACE CREAM (Drug) $885.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Dallas
Dr. Joe Blumenau, M.d., F.a.a.f.p, M.D., F.A.A.F.P
Family Medicine — Payments: $437,740
Family Medicine $437,740
Chrisette Dharmagunaratne, M.d, M.D
Family Medicine — Payments: $325,780
Family Medicine $325,780
Scott Conard, Md, MD
Family Medicine — Payments: $152,327
Family Medicine $152,327
Andrew Applewhite, Md, MD
Family Medicine — Payments: $83,645
Family Medicine $83,645
Shiwali Rai, Md, MD
Family Medicine — Payments: $43,143
Family Medicine $43,143
Dr. Paul Worrell, D.o, D.O
Family Medicine — Payments: $36,341
Family Medicine $36,341